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BACKGROUND & AIMS: The a4b7 integrin is a validated target
in inﬂammatory bowel disease. This randomized, phase 2b,
placebo-controlled, double-blind study evaluated the efﬁcacy
and safety of the anti-a4b7 antibody abrilumab in patients with
moderate-to-severe ulcerative colitis despite treatment with
conventional therapies. METHODS: Patients (total Mayo Score
6–12, recto-sigmoidoscopy score 2) with inadequate response
or intolerance to conventional therapies were randomized to
receive subcutaneous abrilumab (7, 21, or 70 mg) on day 1,
weeks 2 and 4, and every 4 weeks; abrilumab 210 mg on day 1;
or placebo. The primary end point was remission (total Mayo
Score 2 points, no individual sub-score >1 point) for the 2
highest dosages at week 8. Key secondary end points were
response and mucosal healing (centrally read) at week 8.
RESULTS: For 354 patients who received 1 dose of investi-
gational product (placebo, n ¼ 116; 7 mg, n¼ 21; 21 mg, n¼ 40;
70 mg, n ¼ 98; 210 mg, n ¼ 79), non-adjusted remission rates at
week 8 were 4.3%, 13.3%, and 12.7% for the placebo and
abrilumab 70-mg and 210-mg groups, respectively (P < .05 for
70 and 210 mg vs placebo); odds of achieving remission were
signiﬁcantly greater with abrilumab 70 mg (odds ratio 3.35;
90% CI 1.41–7.95; P ¼ .021) and 210 mg (odds ratio 3.33; 90%
conﬁdence interval 1.34–8.26; P ¼ .030) than with placebo.
Response and mucosal healing rates with these dosages also
were signiﬁcantly greater than with placebo. Higher baseline
a4b7 levels on naïve CD4
þ T cells were a prognostic indicator for
overall outcome, but not a predictive biomarker of abrilumab
response. There were no cases of progressive multifocal leu-
koencephalopathy or deaths. CONCLUSIONS: Abrilumab treat-
ment for 8 weeks induced remission, clinical response, and
mucosal healing in patients with moderate-to-severe ulcerative
colitis. ClinicalTrials.gov, number NCT01694485.
Keywords: Ulcerative Colitis; Abrilumab; a4b7.
Ulcerative colitis (UC) is an idiopathic inﬂammatorybowel disease of the colon.1–3 Treatment of UC in-
cludes medical management and colectomy.3–5 Goals of
therapy include inducing and maintaining clinical and
endoscopic remission, improving quality of life, decreasing
the need for long-term corticosteroid therapy, and mini-
mizing cancer risk.6 Patients with moderate-to-severe UC
are usually treated with oral corticosteroids; immunomod-
ulators, such as azathioprine and 6-mercaptopurine; and
biologics, including tumor necrosis factor (TNF) antago-
nists2,7 or the integrin antagonist vedolizumab.7 Despite
advances in treatment, many patients with UC do not ach-
ieve symptomatic and endoscopic remission and ultimately
might require colectomy.7 Therefore, there is an unmet need
for drugs with improved beneﬁt–risk proﬁles and other
modes of action to treat moderate-to-severe UC.
The inﬂux of immune cells into gut mucosa, mediated
through integrin-dependent leukocyte tethering, rolling, and
arrest, plays an important role in inﬂammatory bowel dis-
ease pathogenesis.8 The cellular adhesion molecule a4b7
integrin is a member of the integrin family that mediates
stable adhesion to high endothelial venules through the
mucosal addressin cell adhesion molecule-1 and promotes
migration of lymphocytes across the endothelial wall.9 The
a4b7 integrin is expressed on circulating lymphocytes,
particularly on a subset of CD4þCD45RA memory T
cells.10,11 Restricting homing of lymphocytes to the gastro-
intestinal tract, by blocking essential integrin-mediated in-
teractions, has been an area of intensive clinical research
over the past 2 decades. Selective targeting of gut lympho-
cyte trafﬁcking by inhibiting the a4b7 pathway was achieved
in patients with UC and Crohn’s disease with intravenously
administered vedolizumab, which was approved by the US
Abbreviations used in this paper: AE, adverse event; CI, conﬁdence in-
terval; CRP, C-reactive protein; FCP, fecal calprotectin; IP, investigational
product; IPIM, investigational product instruction manual; NRI, nonre-
sponder imputation; OR, odds ratio; PK, pharmacokinetic; PML, pro-
gressive multifocal leukoencephalopathy; SAE, serious adverse event; SC,
subcutaneous; SD, standard deviation; TNF, tumor necrosis factor; UC,
ulcerative colitis.
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Food and Drug Administration for induction and mainte-
nance therapy in these indications.12 Therefore, targeting
gut-selective lymphocyte trafﬁcking is a promising thera-
peutic strategy in inﬂammatory bowel disease.13
Abrilumab is a human monoclonal immunoglobulin G2
antibody that selectively targets a4b7 and blocks interaction
with mucosal addressin cell adhesion molecule-1.14 Abrilu-
mab is extensively absorbed after subcutaneous (SC) dosing
with high bioavailability (82%–99%) and a long half-life
(w31 days).15 Receptor occupancy data from healthy in-
dividuals and 4 patients with UC showed repeated dosing of
abrilumab 21 mg or a single dose of 210 mg resulted in
near maximal receptor occupancy on peripheral blood-naïve
CD4þ T lymphocytes.15 Abrilumab is formulated for SC
administration, which could confer a practical advantage for
patients over intravenous infusion. In this phase 2 study, we
evaluated the efﬁcacy, safety, pharmacokinetics (PK), phar-
macodynamics, and receptor occupancy of abrilumab in
patients with moderate-to-severe UC.
Methods
This multicenter, randomized, double-blind, placebo-
controlled, parallel-group, multiple-dose, phase 2 induction
and sustained remission trial evaluated patients with active
moderate-to-severe UC who did not respond or no longer
responded to conventional therapies (NCT01694485). Patient
enrollment began on November 16, 2012, and data were
collected through October 26, 2015, at 92 centers in North
America, Europe, and Australia. The independent ethics com-
mittee or institutional review board at each center reviewed
and approved the study protocol. All patients provided writ-
ten and informed consent before participation. The trial was
conducted in accordance with International Conference on
Harmonisation Good Clinical Practice regulations and
guidelines. All authors had access to study data and reviewed
and approved the ﬁnal manuscript.
Study Design
The study consisted of a screening period (minimum 7 and
up to 30 days) to establish patient eligibility followed by a
24-week, placebo-controlled, double-blind treatment period
(Supplementary Figure 1). At the end of the double-blind
period (week 24), patients could enter an open-label period
of 108 weeks. Patients were eligible to enter the open-label
period of the study early if they did not achieve a response at
week 8 and had an inadequate response at week 12 or later or
if they experienced disease worsening after achieving response
and/or remission at week 8. Failure to achieve response at
week 8 was deﬁned as failure to achieve a decrease from
baseline in total Mayo Score 3 points and 30% decrease
from baseline. Inadequate response at week 12 or later was
deﬁned as failure to achieve a 2-point decrease and 25%
improvement in partial Mayo Score compared with screening
and minimum partial Mayo Score 5 points. Disease worsening
was deﬁned as an increase in partial Mayo Score 3 points
from the week-8 value and minimum partial Mayo Score 5
points with recto-sigmoidoscopy sub-score 2.
Patients were planned to be randomized in a 2:1:2:2:2 ratio
to SC placebo or abrilumab at 7 mg, 21 mg, 70 mg (on day 1,
week 2, week 4, and every 4 weeks thereafter until week 24), or
210 mg (on day 1 followed by placebo in weeks 2 and 4 and
every 4 weeks thereafter until week 24), respectively. Patients
who progressed to the open-label phase of the study received SC
abrilumab 210 mg once every 3 months. Additional details about
dosing are presented in the Supplemental Materials. Assignment
to treatment groups was based on a computer-generated
randomization schedule. The randomization schedule was
generated using a permuted block design within each stratum
based on prior TNF antagonist use and participation in the PK
sub-study to guarantee comparability of compared groups in the
PK sub-study and had no inﬂuence on the main study. Prior TNF
antagonist use was allowed in a maximum of 50% of patients
enrolled in the study. Some members of the sponsor not part of
the study team were unblinded to treatment allocation during
the primary analysis (when all patients completed the week-12
visit or discontinued); all patients, investigators, and sponsor
study team members remained blinded through the end of the
double-blind period.
Study Population
Patients 18–65 years of age with moderate-to-severe active
UC conﬁrmed histopathologically and endoscopically (total
Mayo Score 6–12 and centrally read [Robarts, Clinical Trials;
London, Canada] Mayo endoscopic sub-score 2 before base-
line) who exhibited inadequate or loss of response or intoler-
ance to immunosuppressants, TNF antagonists, and/or
corticosteroids (excluding patients in the United States) were
eligible. Patients also were required to be free of clinically
signiﬁcant and unexplained neurologic signs and symptoms
during screening and before randomization.
Concomitant medications deemed necessary to provide
adequate supportive care were allowed during the study.
Concurrent use of stable doses of 5-aminosalicylic acid and/or
oral prednisone or equivalent up to 20 mg/day was permitted
WHAT YOU NEED TO KNOW
BACKGROUND AND CONTEXT
Despite the available treatment options, many patients
with ulcerative colitis (UC) do not respond to therapy.
Therefore, there is a need for new UC therapies.
NEW FINDINGS
Abrilumab, an anti-a4b7 antibody treatment, for 8 weeks
resulted in signiﬁcantly greater remission, response, and
mucosal healing rates versus placebo. Higher baseline
a4b7 on naïve CD4þ T cells predicted overall outcome.
LIMITATIONS
A systematic misalignment in randomization resulted in
some patients receiving the incorrect dose; power to
detect treatment differences was maintained. This short-
term study did not fully assess treatment effects beyond
8 weeks.
IMPACT
Abrilumab is an effective treatment for UC. The data also
conﬁrm the targeting of the a4b7 pathway for UC
treatment.
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in patients taking those medications for 2 weeks before
baseline. Oral corticosteroid dose was stable through week 12;
for patients in remission at week 8, the dose was decreased by
2.5 mg/week until discontinuation, while the patient was in
symptomatic remission. The 5-aminosalicylic acid dosage was
kept stable from day 1 through week 24; acetylsalicylic acid–
based enemas were not allowed during this period. Concur-
rent use of azathioprine or 6-mercaptopurine was permitted if
treatment was initiated 12 weeks before baseline and had
been at a stable dosage for 8 weeks before baseline. Simul-
taneous treatment with methotrexate up to a stable dosage of
25 mg/week was permitted in patients who took the medica-
tion for 8 weeks before baseline. Immunomodulators were
administered at stable dosages through week 8 and were
withdrawn at the week-8 study visit.
Patients were excluded from the study if they met any of the
following exclusion criteria: disease limited to the rectum; toxic
megacolon; Crohn’s disease; history of subtotal or total colectomy;
bowel surgery within 24 weeks of baseline; history of gastroin-
testinal surgery within 8 weeks of baseline; and primary scle-
rosing cholangitis. Patients who had received TNF antagonists
within 2 months or 5 times the respective elimination half-life
(whichever was longer) before baseline or vedolizumab, ritux-
imab, efalizumab, or natalizumab at any time were excluded.
Investigational Products and Treatment
Procedure
Abrilumab was provided as a sterile, colorless to slightly
yellow, frozen liquid at 70 mg/mL in glass vials containing an
approximately 1-mL deliverable volume for single use only.
Placebo was provided as a frozen liquid identical in appearance,
storage, and packaging to abrilumab. Unblinded pharmacists
used vialed placebo to dilute vialed abrilumab to prepare lower
doses. Placebo and abrilumab were administered by SC injec-
tion. Irrespective of treatment arm, blinding was maintained by
all patients receiving 3 separate SC injections for a total volume
of 3 mL per dose. During the open-label period, patients
received abrilumab 210 mg every 3 months by 3 SC injections
for a total volume of 3 mL.
Assessments
The primary end point was remission at week 8 (total Mayo
Score 2 points, with no individual sub-score >1 point). Key
secondary end points were response at week 8 (decrease from
baseline in total Mayo Score 3 points and 30% decrease
from baseline, with an accompanying decrease in the sub-score
for rectal bleeding 1 point or an absolute sub-score for rectal
bleeding 0 or 1) and mucosal healing at week 8 (absolute
endoscopic sub-score 0 or 1). Another secondary end point was
sustained remission at weeks 8 and 24. For safety end points,
data from all randomized patients who received 1 dose of
double-blind treatment were assessed based on actual treat-
ment received; there was no statistical testing for safety ana-
lyses. Safety was assessed by monitoring adverse events (AEs),
serious AEs (SAEs), signiﬁcant changes in laboratory values and
vital signs, and anti-abrilumab antibodies. The neurologic sta-
tus of patients was closely monitored throughout the study and
for up to 24 months after the last dose of investigational
product (IP) using a prespeciﬁed checklist. An external inde-
pendent progressive multifocal leukoencephalopathy (PML)
adjudication committee with expertise in neurologic manifes-
tations of PML reviewed clinical data and applied a prespeciﬁed
diagnostic algorithm for PML.
Immunogenicity Assessment
Serum anti–abrilumab-binding antibodies were assessed
using validated electro-chemiluminescent immunoassays:
screening assay, speciﬁcity assay, and quasi-quantitative titra-
tion assay. The immunoassay (binding) drug tolerance was 25
mg/mL. Anti–abrilumab-neutralizing antibodies were analyzed
for samples positive for anti–abrilumab-binding antibodies
using a cell-based (CHO-a4b7 cell) assay. The drug tolerance of
the neutralizing antibody assay was 0.063 mg/mL.
Pharmacokinetic and Pharmacodynamic
Assessments
Pharmacokinetic. Characterization of abrilumab PK and
the exposure–response relation for efﬁcacy were exploratory
end points. The bioanalytical assay to determine abrilumab
serum concentration is described elsewhere.15,16 Additional
details about the PK assay and analyses are presented in the
Supplementary Materials.
Fecal Calprotectin and Serum C-Reactive Protein.
The effects of abrilumab on fecal calprotectin (FCP) and serum
concentrations of C-reactive protein (CRP) were exploratory
end points. Fecal samples were collected within 3 days before
or during speciﬁed study visits for quantitative determination
of FCP. Covance Central Laboratory Services (Princeton, NJ)
performed the diagnostic (enzyme immunoassay) test.
Flow Cytometry. A sub-study of 129 patients (48, 7, 21, 37,
and 29 patients in the placebo, abrilumab 7-mg, 21-mg, 70-mg,
and 210-mg arms, respectively), selected by geographic location
near the central laboratory, was analyzed for baseline and post-
dose changes in peripheral blood a4b7 receptor occupancy.
Additional details about receptor occupancy and ﬂow cytometry
methods are presented in the Supplementary Materials.
Statistical Analysis
Sample size considerations assumed the week-8 remission
rates would be 7.5%, 12%, 16.5%, 21%, and 21% in the pla-
cebo and abrilumab 7-mg, 21-mg, 70-mg, and 210-mg groups,
respectively, based on historical data and a linear dose–
response relation. A total number of 360 patients was esti-
mated based on the overall linear trend test to reach 80%
power at a 2-sided .10 signiﬁcance level. With a randomization
ratio of 2:1:2:2:2 intended to allocate fewer patients to a
potentially non-efﬁcacious dose, planned sample sizes were 80,
40, 80, 80, and 80 patients for the placebo and abrilumab 7-mg,
21-mg, 70-mg, and 210-mg groups, respectively, with 77%
power to detect differences between each of the abrilumab
210-mg and 70-mg groups vs placebo using a .10 2-sided test,
assuming a 5% dropout rate.
Early during trial conduct, routine PK analyses by the un-
blinded clinical pharmacology group reported a systematic
inconsistency in expected exposures for the 7-mg and 21-mg
dose cohorts (Supplementary Figure 2). The study was imme-
diately paused for investigation, which showed a consistent
discrepancy between the IP instruction manual (IPIM)
description of vial positions and the actual vial positions in the
IP package (Supplementary Figure 3). The vial in the lower-left
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corner (“position A” in Supplementary Figure 3) of the package
was—according to the IPIM—intended to contain active IP
(abrilumab); however, it was placebo. Likewise, the vial in
“position C” was intended to be placebo, and it was active IP.
Therefore, all patients randomized to abrilumab 21 mg until
this point received placebo and all patients randomized to
abrilumab 7 mg received 70 mg systematically. This was the
sole error and unrelated to the Interactive Web Response
System. As a consequence, the study up to the pause was
randomized to 3 arms—placebo, 70 mg, and 210 mg—with a
randomization ratio of 4:3:2; after the pause, the study was
randomized to 5 arms—placebo, 7 mg, 21 mg, 70 mg, and 210
mg—with a randomization ratio of 2:1:2:2:2. Because the study
remained blinded to randomized treatment assignment, trial
integrity was maintained. The issue was termed a “misalign-
ment of active (ie, abrilumab) vial positions in the package vs
the IPIM” (also referred to as “misalignment”).
Study sites, independent ethics committees or institutional
review boards, and regulatory authorities were notiﬁed of this
systematic error. Once the discrepancy was corrected and
affected patients completed their double-blind treatment period,
the study resumed enrollment and randomization per protocol.
The protocol statistical analysis section was amended to account
for the misalignment before study pause and updated to
prespecify the appropriate analysis method before study un-
blinding. The sponsor study team, patients, and study sites
remained blinded throughout this process. The misalignment
resulted in aﬁnal randomization allocation of 116, 21, 40, 98, and
79 patients in the placebo and abrilumab 7-mg, 21-mg, 70-mg
and 210-mg arms, respectively (Supplementary Figure 2).
The study was powered for formal statistical testing of the
abrilumab 70-mg and 210-mg groups. To account for multi-
plicity of statistical testing, primary and key secondary end
points for the 2 highest doses of abrilumab (70 and 210 mg)
were tested at the end of the 8-week induction period under a
sequential framework at a 2-sided signiﬁcance level of .10
using the Bonferroni-based chain procedure.17 Key secondary
end points of response and mucosal healing were initially
tested using .05 simultaneously until the hypothesis of the
other chain was rejected, so end points could be re-tested at
the .10 signiﬁcance level. A single logistic regression model
containing all abrilumab dose groups, placebo, baseline total
Mayo Score, and stratiﬁcation factors (prior vs no prior TNF
antagonist use and enrollment pre- vs post-protocol amend-
ment) was ﬁt. The stratiﬁcation factor of prior vs no prior
TNF antagonist use was used in randomization. Odds ratios
(ORs), 90% conﬁdence intervals (CIs), and P values were
obtained for pairwise comparisons of each abrilumab dose
with placebo using this model, with nonresponder imputation
(NRI). Non-adjusted (observed NRI) and adjusted (by logistic
regression model) estimates of remission rates were calcu-
lated. Considering the sample size and the ﬁnal randomization
allocation, for the primary end point there was approximately
87% and 84% power to detect differences between the
abrilumab 70-mg and 210-mg groups, respectively, vs placebo
using a .10 2-sided test. The relation of the percentage of
patients in remission was plotted against observed deciles of
abrilumab serum trough concentration as part of the
exposure–response analysis of data. Remission rates for
different decile groups were tested for signiﬁcance against the
placebo remission rate.
Postulated response and mucosal healing rates based on
sequential testing were 25%, 45%, and 45% in the placebo,
abrilumab 70-mg, and abrilumab 210-mg groups, respectively.
For the abrilumab 70-mg group and the 210-mg group vs
placebo, the power to detect differences was approximately
85% for response and 81% for mucosal healing using a .05 2-
sided test. The association between baseline a4b7 level and
change in total Mayo Score was analyzed based on baseline-
adjusted analysis of variance for the change from baseline
Mayo Score; the analysis included factors for baseline a4b7,
dose, and interaction.
Results
Patient Disposition
Of 359 patients randomized, 354 entered the double-
blind phase; 116 patients (33%) received placebo and 238
(67%) received abrilumab. A systematic misalignment be-
tween IP secondary packaging and the IPIM led to a ﬁnal
allocation of placebo (n ¼ 116), 7 mg (n ¼ 21), 21 mg (n ¼
40), 70 mg (n ¼ 98), and 210 mg (n ¼ 79). Importantly, the
misalignment did not compromise the study blind and data
were analyzed per the protocol amendment described in the
Methods.
At week 8, 332 patients (94%) completed the initial 8-
week double-blind period (abrilumab, 226 [95%]; placebo,
106 [91%]); 6 patients (3 abrilumab, 3 placebo) completed
but missed the week-8 assessment (Supplementary
Figure 4). Overall, the most common reasons for discon-
tinuation before week 8 were full withdrawal of consent
(abrilumab, 5 [2.1%]; placebo, 1 [0.9%]), AEs (abrilumab, 1
[0.4%]; placebo, 4 [3.4%]), and requirement for alternative
therapy (abrilumab, 3 [1.3%]; placebo, 2 [1.7%]). Of 354
patients who received double-blind treatment, 153 (43%)
completed the 24-week double-blind period (abrilumab,
118 [50%]; placebo, 35 [30%]). The most common reason
for discontinuation of the double-blind period before week
24 was lack of response (abrilumab, 78 [33%]; placebo, 54
[47%]). Of 354 patients who received double-blind treat-
ment, 311 (88%) entered the open-label period.
Patient Characteristics
Baseline demographics and disease characteristics were
similar among treatment groups, with no notable differ-
ences among the abrilumab 70-mg, abrilumab 210-mg, and
placebo groups (Table 1). Overall, mean age was 40.1 years
(standard deviation [SD] 12.4). Mean baseline total Mayo
Score based on central blinded reading of sigmoidoscopies
was 8.9 (SD 1.5) and mean duration of disease was 8.6 years
(SD 6.7). Approximately 51% of patients had prior exposure
to 1 TNF antagonist and 44% used oral corticosteroids at
baseline. Median overall baseline FCP was 579 mg/kg, and
median baseline CRP was 4.8 mg/L.
Efﬁcacy
Primary End Point. Non-adjusted remission rates
(total Mayo Score 2 points with no individual sub-score
>1 point) at week 8 were 4.3% for placebo and 0.0%,
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Table 1.Demographic and Disease Characteristics at Baseline
Characteristic Placebo (n ¼ 116)
Abrilumab
Total (N ¼ 354)
7 mg Q4W
(n ¼ 21)
21 mg Q4W
(n ¼ 40)
70 mg Q4W
(n ¼ 98)
210 mg
(n ¼ 79) All (N ¼ 238)
Men, n (%) 80 (69.0) 14 (66.7) 28 (70.0) 67 (68.4) 48 (60.8) 157 (66.0) 237 (66.9)
Caucasian, n (%) 108 (93.1) 19 (90.5) 39 (97.5) 87 (88.8) 77 (97.5) 222 (93.3) 330 (93.2)
Age (y), median (IQR) 40.0 (29.5–50.5) 48.0 (31.0–54.0) 36.5 (29.0–47.0) 39.0 (30.0–48.0) 39.0 (31.0–50.0) 39.0 (31.0–49.0) 39.0 (30.0–50.0)
BMI (kg/m2), mean (SD) 25.1 (4.6) 24.8 (4.7) 25.0 (4.4) 26.0 (5.8) 25.3 (4.2) 25.5 (5.0) 25.3 (4.8)
Duration of UC (y),
median (IQR)
6.4 (3.2–11.2) 7.4 (4.3–11.3) 5.7 (3.4–10.0) 7.4 (3.4–13.6) 8.4 (3.5–12.5) 7.2 (3.5–12.3) 7.1 (3.4–11.8)
Total Mayo Score,a
median (IQR)
9.0 (8.0–10.0) 8.0 (7.0–9.0) 8.5 (7.0–10.0) 9.0 (8.0–10.0) 9.0 (8.0–10.0) 9.0 (8.0–10.0) 9.0 (8.0–10.0)
Partial Mayo Score,
mean (SD)
6.3 (1.4) 5.6 (1.3) 6.0 (1.4) 6.3 (1.3) 6.4 (1.2) 6.2 (1.3) 6.2 (1.3)
Albumin (g/L), mean (SD) 37.6 (4.7) 38.9 (4.7) 39.2 (6.1) 38.7 (4.6) 38.8 (4.1) 38.8 (4.7) 38.4 (4.7)
FCP (mg/kg), median (IQR) 584.0 (193.3–1444.2) 568.4 (171.7–895.5) 611.8 (465.2–1161.6) 522.8 (162.5–963.3) 587.6 (340.7–1209.1) 574.5 (235.6–1112.3) 578.5 (211.4–1185.0)
CRP (mg/L), median (IQR) 6.4 (2.0–14.0) 5.0 (2.2–15.4) 2.2 (1.0–7.9) 5.0 (1.4–10.3) 4.1 (1.6–11.8) 4.3 (1.4–11.0) 4.8 (1.5–12.7)
Prior TNF antagonist, n (%) 72 (62.1) 5 (23.8) 10 (25.0) 55 (56.1) 38 (48.1) 108 (45.4) 180 (50.8)
Prior immunomodulator
use, n (%)
106 (91.4) 17 (81.0) 33 (82.5) 89 (90.8) 59 (74.7) 198 (83.2) 304 (85.9)
Immunomodulator use at
baseline, n (%)
48 (41.4) 6 (28.6) 17 (42.5) 32 (32.7) 21 (26.6) 76 (31.9) 124 (35.0)
Oral corticosteroid use at
baseline, n (%)
53 (45.7) 6 (28.6) 16 (40.0) 49 (50.0) 32 (40.5) 103 (43.3) 156 (44.1)
5-aminosalicylate use at
baseline, n (%)
73 (62.9) 13 (61.9) 29 (72.5) 70 (71.4) 60 (75.9) 172 (72.3) 245 (69.2)
BMI, body mass index; IQR, interquartile range; Q4W, every 4 weeks.
aBased on central read of ﬂexible recto-sigmoidoscopy.
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2.5%, 13.3%, and 12.7% for the abrilumab 7-mg, 21-mg, 70-
mg, and 210-mg groups, respectively (Figure 1). The odds of
achieving remission at week 8 were signiﬁcantly greater
with the abrilumab 70-mg and 210-mg doses vs placebo (70
mg: OR 3.35; 90% CI 1.41–7.95; P ¼ .021; 210 mg: OR 3.33;
90% CI 1.34–8.26; P ¼ .030; Table 2).
Key Secondary End Points. Non-adjusted response
rates at week 8 were 25.9% for placebo and 14.3%, 50.0%,
49.0%, and 46.8% for the abrilumab 7-mg, 21-mg, 70-mg,
and 210-mg groups, respectively (Figure 2). The odds of
achieving response at week 8 were signiﬁcantly greater
with the abrilumab 70-mg and 210-mg doses vs placebo (70
mg: OR 2.78; 90% CI 1.71–4.52; P < .001; 210 mg: OR 2.57;
90% CI 1.53–4.51; P ¼ .003; Supplementary Table 1). Non-
adjusted mucosal healing rates at week 8 were 21.6% for
placebo and 14.3%, 15.0%, 32.7%, and 29.1% for the abri-
lumab 7-mg, 21-mg, 70-mg, and 210-mg groups, respec-
tively (Figure 3). The odds of achieving mucosal healing
rates at week 8 were signiﬁcantly greater with the abrilu-
mab 70-mg and 210-mg doses vs placebo (70 mg: OR 2.34;
90% CI 1.35–4.07; P ¼ .011; 210 mg: OR 2.10; 90% CI 1.15–
3.82; P ¼ .041; Supplementary Table 2).
Other Secondary and Exploratory Clinical End
Points. Subgroup analyses were conducted for primary
and key secondary end points in patients with prior TNF
antagonist treatment failure vs no prior TNF antagonist use.
Analysis of patients by prior TNF antagonist failure indi-
cated greater remission rates for patients treated with the
abrilumab 70-mg and 210-mg doses vs placebo (70 mg: OR
5.14; 90% CI 1.11–23.81; P ¼ .079; 210 mg: OR 11.06; 90%
CI 2.39–51.13; P ¼ .010; Figure 1). Greater response (OR
2.91; 90% CI 1.45–5.84; P ¼ .012; Figure 2) and mucosal
healing rates (OR 3.59; 90% CI 1.60–8.08; P ¼ .009;
Figure 3) were observed for patients with prior TNF
antagonist failure treated with abrilumab 210 mg vs pla-
cebo. Nominal P values for remission were not signiﬁcant in
patients with no prior TNF antagonist use (Table 2); how-
ever, nominal P values were signiﬁcant for response in the
21- and 70-mg groups and mucosal healing in the 70-mg
group (Supplementary Tables 1 and 2).
There was no indication of treatment effect of abrilumab
for remission and response at week 24 (Supplementary
Tables 3 and 4). For mucosal healing at week 24, there
was an indication of treatment effect for the abrilumab 70-
mg group (Supplementary Table 5). Of 354 randomized
patients who received 1 dose of IP, 140 (40%) had total
Mayo Scores at weeks 8 and 24 and were evaluable for
sustained remission. Among evaluable patients, 8 of 46
(17.4%) on abrilumab 70 mg, 3 of 32 (9.4%) on abrilumab
210 mg, and 3 of 32 (9.4%) on placebo had remission at
weeks 8 and 24 (Supplementary Table 6). Using NRI for
patients not evaluable for sustained remission, the adjusted
sustained remission rate difference for abrilumab 70 mg vs
placebo was 5.8% (90% CI 0.6 to 10.4), with OR 2.94
(90% CI 1.03–8.36); the adjusted sustained remission rate
difference for abrilumab 210 mg vs placebo was 1.0% (90%
CI 4.7 to 4.6), with OR 1.32 (90% CI 0.38–4.56). Of pa-
tients who achieved response at week 8, 12 of 30 (40.0%),
21 of 48 (43.8%), and 8 of 37 (21.6%) achieved remission at
week 24 in the placebo, abrilumab 70-mg, and abrilumab
210-mg groups, respectively, using NRI. Steroid-free
remission at week 24 was 5 of 116 (4.3%), 7 of 98
(7.1%), and 4 of 79 (5.1%) patients in the placebo, abrilu-
mab 70-mg, and abrilumab 210-mg groups, respectively,
using NRI (Supplementary Table 7).
Safety
Adverse Events. Patients reported AEs at similar in-
cidences across treatment groups through week 24: 79
(68.1%) patients in the placebo and 150 (63.0%) patients in
all abrilumab groups reported 1 treatment-emergent AE of
any grade (Table 3). Mild injection site reactions were re-
ported by 4 (3.4%) patients in the placebo group, 5 (5.1%)
in abrilumab 70-mg group, and 1 (1.3%) in abrilumab 210-
mg group. Grade 3 AEs were reported by 16 (13.8%)
patients in the placebo group and 24 (10.1%) across all
abrilumab groups. AEs led to discontinuation in 10 (8.6%)
patients in the placebo group and 8 (3.4%) in the abrilumab
groups. SAEs were reported by 14 (12%) and 16 (6.7%)
patients in the placebo and abrilumab groups, respectively.
Grade 3 SAEs were reported by 9.5% and 5.5% of patients
in the placebo and abrilumab groups, respectively. The only
SAE reported by more than 1 patient treated with abrilumab
Figure 1. Non-adjusted remission rates for all patients, pa-
tients with prior TNF antagonist failure, and patients naïve to
TNF antagonist at week 8. Patients received SC placebo or
abrilumab 7 mg, 21 mg, or 70 mg (on day 1, week 2, week 4,
and Q4W thereafter) or a single dose of abrilumab 210 mg (on
day 1 followed by placebo weeks 2 and 4 and Q4W there-
after). Remission at week 8 was indicated by a total Mayo
Score 2 points, with no individual sub-score >1 point. Non-
adjusted remission rates, 90% CIs, and P values were
obtained from a logistic regression model for pairwise com-
parisons of abrilumab dose groups vs placebo group with
adjustment for stratiﬁcation factors (prior vs no prior TNF
antagonist use) and for baseline total Mayo Score using NRI;
bars represent 90% CIs around means. Nominal P values are
reported for exploratory end points without adjustment for
multiple testing. *Signiﬁcant at P < .1; †nominal P < .1. N,
number of patients in full analysis set; Q4W, every 4 weeks.
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was worsening of UC. No patient died or reported PML
during the study. Ten (8.6%) patients in the placebo group
and 9 (3.8%) in the abrilumab groups reported benign,
malignant, and unspeciﬁed neoplasms (Table 3).
Immunogenicity. Post-baseline anti-abrilumab anti-
body evaluation from 348 patients (placebo, 114; abrilu-
mab, 234) indicated 1 patient in the abrilumab 70-mg group
and 1 in the abrilumab 210-mg group were positive for
anti–abrilumab-binding antibodies. No neutralizing anti-
bodies were detected.
Pharmacokinetics and Pharmacodynamics
Pharmacokinetics. Of 63 patients who participated in
the PK sub-study, 23 had enough data for PK parameter
evaluation: 3 patients in the abrilumab 7-mg group, 6 in the
21-mg group, 5 in the 70-mg group, and 9 in the 210-mg
group. Based on the abrilumab PK proﬁle and parameters
analysis, the mean values for maximum observed concen-
tration were 2.48 mg/mL (SD 3.06), 6.43 mg/mL (2.80), 18.3
mg/mL (9.08), and 27.5 mg/mL (10.4) for the abrilumab 7-
mg, 21-mg, 70-mg, and 210-mg arms, respectively. The
median times to maximum observed concentration were
8.0, 6.5, 7.0, and 7.9 days for abrilumab 7 mg, 21 mg, 70 mg,
and 210 mg, respectively (Supplementary Table 8). After SC
administration of abrilumab 210 mg every 3 months in the
open-label period, with the number of patients varying
greatly (14–241 patients) depending on time point, mean
trough concentrations ranged from 3.55 to 5.65 mg/mL.
Mean (SD) PK concentrations at weeks 8 and 24 are pre-
sented in Supplementary Table 9.
Exposure–Response Analysis. Exposure–response
analysis of remission rate and PK data demonstrated that
patients in decile groups with mean trough levels of 10
mg/mL showed signiﬁcant remission vs placebo, and
maximal observed remission rates were associated with
mean trough concentrations >10 mg/mL (Supplementary
Figure 5).
Change in CRP and FCP. CRP and FCP concentrations
for weeks 8 and 24 are presented in Supplementary
Tables 10 and 11, respectively. Up to week 8, treatment-
related decreases were observed for the abrilumab 70-mg
and 210-mg groups vs placebo for FCP, but not for CRP.
At week 8, post hoc analyses showed only patients in the
abrilumab 70-mg arm attained a 50% decrease of FCP from
baseline (adjusted rate) vs placebo; treatment difference
was 17% (90% CI 3.6–27.9) for the abrilumab 70-mg group
vs placebo (Supplementary Table 11). The nominal P value
for the corresponding OR vs placebo was .03. In contrast,
the CRP treatment difference vs placebo at week 8 appeared
to be minimal for all abrilumab doses.
Sub-study of Immunophenotyping Receptor
Occupancy With Absolute Counts. Assessment of Free
a4b7. Abrilumab treatment led to a reversible decrease of
free a4b7 levels on naïve CD4
þ T cells in the peripheral
blood of patients with UC (Supplementary Figure 6A).
Maximal decrease in free a4b7 levels was approximately
90% from baseline. Maximal decrease in free a4b7 levels
compared with baseline was observed at the ﬁrst post-dose
assessment (week 2) for all dosages of abrilumab. For pa-
tients in the abrilumab 7-mg multidose arm, the decrease
persisted through week 4. From weeks 8 through 24, mean
free a4b7 levels began to normalize but remained 65%
decreased compared with baseline and were not statistically
different from means at weeks 2 and 4. For patients in the
21-mg and 70-mg multiple-dose arms, maximal decrease in
free a4b7 levels persisted at nearly those low levels through
week 24. For patients in the 210-mg single-dose arm,
Table 2.Summary of Remission at Week 8
Placebo
Abrilumab
7 mg Q4W 21 mg Q4W 70 mg Q4W 210 mg
All patients, N 116 21 40 98 79
Non-adjusted remission rate using NRI, n (%) 5 (4.3) 0 1 (2.5) 13 (13.3) 10 (12.7)
Adjusted remission rate using NRI, % 4.4 1.6 2.9 13.5 13.4
Difference, % (90% CI) — 2.9 (5.5 to 5.4) 1.6 (5.2 to 5.5) 9.0 (1.6–14.6) 8.9 (0.8–14.9)
OR (90% CI) 0.34 (0.03–4.33) 0.64 (0.13–3.17) 3.35 (1.41–7.95) 3.33 (1.34–8.26)
P value .49 .64 .021 .030
Patients with TNF antagonist failure, n 70 5 10 50 38
Non-adjusted remission rate using NRI, n (%) 1 (1.4) 0 0 (0) 5 (10) 6 (15.8)
Adjusted remission rate using NRI, % 1.4 11.2 5.5 7.0 13.9
Difference, % (90% CI) — 9.8 (24.3 to 22.4) 4.0 (13.7 to 10.4) 5.5 (2.5 to 10.2) 12.4 (0.9–19.9)
OR (90% CI) 8.68 (0.32–233.49) 3.98 (0.17–94.14) 5.14 (1.11–23.81) 11.06 (2.39–51.13)
P value .28 .47 .079 .010
Patients naïve to TNF antagonist, n 44 16 30 43 41
Non-adjusted remission rate using NRI, n (%) 4 (9.1) 0 1 (3.3) 6 (14.0) 4 (9.8)
Adjusted remission rate using NRI, % 7.3 1.3 2.7 14.0 8.8
Difference, % (90% CI) — 6.0 (9.7 to 6.3) 4.6 (9.9 to 6.3) 6.7 (6.4 to 15.3) 1.5 (10.6 to 8.9)
OR (90% CI) 0.17 (0.01–2.30) 0.36 (0.07–1.85) 2.07 (0.68–6.32) 1.22 (0.38–3.98)
P value .27 .30 .29 .78
NOTE. Remission at week 8 was deﬁned as a total Mayo Score 2 points, with no individual sub-score >1 point.
N, number of patients in full analysis set; n, number of patients who reached remission status at week 8; Q4W, every 4 weeks.
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maximal decrease in free a4b7 levels persisted through
week 8. Intermediate levels of free a4b7 were observed at
weeks 12 and 16, and free a4b7 levels returned to baseline
at week 24.
Assessment of Total a4b7. Abrilumab led to a reversible
decrease in total a4b7 levels in the peripheral blood of pa-
tients with UC. Maximal decrease was approximately 50% of
baseline. Duration of decrease in total a4b7 levels roughly
mirrored the change in free a4b7, including an intermediate
decrease—from 0% to 50%—in total a4b7 levels in the 7-
mg group at weeks 12 and 24 (no patients in the 7-mg
group had a week-16 visit). The 210-mg group likewise
exhibited an intermediate decrease in total a4b7 levels at
weeks 12 and 16, with a return to baseline of total a4b7 at
week 24 (Supplementary Figure 6B). Baseline total a4b7
levels were signiﬁcantly lower in patients who had prior
TNF antagonist failure (Supplementary Figure 7).
Prognostic Biomarker. Mean free and total a4b7 levels
on naïve CD4þ T cells at baseline were signiﬁcantly lower in
patients with UC than in healthy volunteers from previous
abrilumab studies and validation studies (data on ﬁle,
Amgen Inc; P ¼ .001 and P ¼ .0045, respectively). Although
the decrease in the number of a4b7
þ circulating memory
T cells has been observed previously,18 decrease of a4b7
levels on naïve CD4þ T cells in UC was unexpected. There-
fore, we tested whether baseline levels of a4b7 on naïve CD4
þ
T cells could identify patients most likely to respond to
abrilumab. Overall, there was a signiﬁcant linear association
between higher baseline a4b7 levels and greater changes in
total Mayo Score (P ¼ .046; Supplementary Figure 8) and in
mucosal healing (P ¼ .03; data not shown) at week 8. How-
ever, this association was not signiﬁcantly different among
any dose groups (P ¼ .53), with higher baseline levels pre-
dicting a greater change in total Mayo Score and mucosal
healing at week 8 in the placebo group.
Assessment of CD4 T-Cell Subsets. Administration of
abrilumab induced a signiﬁcant post-dose increase in mean
a4b7–high central memory CD4
þ T-cell counts (P ¼ .016 by
analysis of variance) but not in mean circulating or central
memory CD4þ T-cell counts from baseline to week 8
(Supplementary Figure 6C).
Discussion
This randomized phase 2b study demonstrated that
treatment with the anti-a4b7 antibody abrilumab, adminis-
tered as multiple doses of 70 mg or a single dose of 210 mg,
signiﬁcantly improved 8-week remission rates compared
with placebo for patients with moderate-to-severe UC
Figure 2. Non-adjusted response rates for all patients, pa-
tients with prior TNF antagonist failure, and patients naïve to
TNF antagonist at week 8. Patients received SC placebo or
abrilumab at 7 mg, 21 mg, or 70 mg (on day 1, week 2, week
4, and Q4W thereafter) or a single dose of abrilumab 210 mg
(on day 1 followed by placebo weeks 2 and 4 and Q4W
thereafter). Response at week 8 was indicated by a decrease
from baseline in total Mayo Score 3 points and 30%
decrease from baseline, with an accompanying decrease in
the sub-score for rectal bleeding of 1 point or an absolute
sub-score for rectal bleeding 0 or 1. Non-adjusted response
rates, 90% CIs, and P values were obtained from a logistic
regression model for pairwise comparisons of the abrilumab
dose groups vs placebo group with adjustment for stratiﬁ-
cation factors (prior vs no prior TNF antagonist use) and for
baseline total Mayo Score using NRI; bars represent 90% CIs
around means. Nominal P values are reported for exploratory
end points without adjustment for multiple testing. *Signiﬁ-
cant at P < .1; †nominal P < .1. N, number of patients in full
analysis set; Q4W, every 4 weeks.
Figure 3. Non-adjusted mucosal healing rates for all patients,
patients with prior TNF antagonist failure, and patients naïve
to TNF antagonist at week 8. Patients received SC placebo or
abrilumab at 7 mg, 21 mg, 70 mg (on day 1, week 2, week 4,
and Q4W thereafter) or a single dose of abrilumab 210 mg (on
day 1 followed by placebo weeks 2 and 4 and Q4W there-
after). Mucosal healing at week 8 was indicated by a absolute
sub-score for recto-sigmoidoscopy 0 or 1. Non-adjusted
mucosal healing rates, 90% CIs, and P values were ob-
tained from a logistic regression model for pairwise com-
parisons of the abrilumab dose groups vs placebo group with
adjustment for stratiﬁcation factors (prior vs no prior TNF
antagonist use) and for baseline total Mayo Score using NRI;
bars represent 90% CIs around means. Nominal P values are
reported for exploratory end points without adjustment for
multiple testing. *Signiﬁcant at P < .1; †nominal P < .1. N,
number of patients in full analysis set; Q4W, every 4 weeks.
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whose previous conventional therapies had failed. Signiﬁ-
cant improvements also were observed for the 2 dosages of
abrilumab compared with placebo for key secondary efﬁ-
cacy end points of clinical response and mucosal healing at
week 8.
There was no apparent advantage of multiple doses of
70 mg or a single dose of 210 mg of abrilumab, with the 2
dosages resulting in adjusted remission rates of approxi-
mately 13.5%, lower than the 21% anticipated in the sample
size calculation. However, these estimates were 3-fold
greater than that observed with placebo; remission was
achieved for only 4.4% of patients who received placebo,
indicating a refractory UC population. Clinical response was
achieved by almost half the patients and mucosal healing
was achieved by almost one third of patients treated with
abrilumab 70 or 210 mg compared with 26% and 16.8%
who received placebo, respectively. Improvements in these
outcome measures were less clear at week 24. Notably,
treatment effect with the 2 higher dosages of abrilumab at
week 8 was apparent across all prespeciﬁed end points for
patients with prior TNF antagonist failure, suggesting a4b7
inhibition with abrilumab might be a viable treatment
alternative for patients who have lost the response to or
cannot tolerate TNF antagonists. However, in the TNF-naïve
subpopulation, nominal P values for remission rates were
not signiﬁcant as in the overall study population, although
nominal P values for response and mucosal healing rates
were signiﬁcant in the 21- and 70-mg groups, respectively.
However, caution should be observed when interpreting
these subgroup analyses, because the statistical power
required for precise estimates of relative efﬁcacy was
insufﬁcient because of the smaller sample.
Other monoclonal antibodies targeting the a4b7–mucosal
addressin cell adhesion molecule-1 interaction, including
vedolizumab (anti-a4b7) and etrolizumab (anti-b7), are un-
der investigation in clinical trials for UC, with vedolizumab
already approved for treatment of patients with UC and
Crohn’s disease.19 Induction of response observed in the
present trial of abrilumab appeared similar to that observed
in a phase 3 trial using an induction dosage of vedolizumab
300 mg at weeks 0 and 2 (47.1% vs 25.5% in placebo group
at week 6).20 Increases in clinical remission and mucosal
healing rates observed with abrilumab also were similar to
those with vedolizumab at week 6.20 The phase 3 GEMINI I
trial of vedolizumab included a maintenance phase, during
which durability of response was measured in responders
to induction therapy who were re-randomized to continued
administration of vedolizumab vs placebo (drug withdrawal
trial design) for up to 52 weeks.21 In the present, smaller
study of abrilumab, patients continued their original treat-
ment assignment to week 24 irrespective of response at
week 8 (“treat straight through” trial design, which does not
select for responding patients), and sustained remission to
week 24 was assessed as a secondary end point. Although
the odds of sustained remission increased for patients who
continued to take multiple doses of abrilumab 70 mg every
Table 3.Treatment-Emergent Adverse Events Reported by 5% of Patients in Any Treatment Arm in the Safety Population
Adverse event, n (%)
Placebo
n ¼ 116)
Abrilumab
7 mg Q4W
(n ¼ 20)
21 mg Q4W
(n ¼ 40)
70 mg Q4W
(n ¼ 99)
210 mg
(n ¼ 79)
All
(N ¼ 238)
Any 79 (68.1) 9 (45.0) 21 (52.5) 70 (70.7) 50 (63.3) 150 (63.0)
Nasopharyngitis 7 (6.0) 0 6 (15.0) 9 (9.1) 8 (10.1) 23 (9.7)
Ulcerative colitis 9 (7.8) 0 3 (7.5) 11 (11.1) 8 (10.1) 22 (9.2)
Headache 7 (6.0) 1 (5.0) 2 (5.0) 11 (11.1) 8 (10.1) 22 (9.2)
Arthralgia 6 (5.2) 0 4 (10.0) 11 (11.1) 6 (7.6) 21 (8.8)
Fatigue 3 (2.6) 0 1 (2.5) 8 (8.1) 3 (3.8) 12 (5.0)
Diarrhea 1 (0.9) 0 3 (7.5) 3 (3.0) 5 (6.3) 11 (4.6)
Nausea 4 (3.4) 0 2 (5.0) 4 (4.0) 5 (6.3) 11 (4.6)
Neoplasma 10 (8.6) 2 (9.5) 1 (2.5) 2 (2.0) 4 (5.1) 9 (3.8)
Anemia 2 (1.7) 0 3 (7.5) 2 (2.0) 2 (2.5) 7 (2.9)
Cough 2 (1.7) 0 0 5 (5.1) 2 (2.5) 7 (2.9)
Abdominal pain 5 (4.3) 1 (5.0) 3 (7.5) 1 (1.0) 1 (1.3) 6 (2.5)
Injection site reaction 4 (3.4) 0 0 5 (5.1) 1 (1.3) 6 (2.5)
Hypertension 1 (0.9) 0 0 5 (5.1) 0 5 (2.1)
Inﬂuenza 4 (3.4) 2 (10.0) 0 2 (2.0) 0 4 (1.7)
Candida infection 0 2 (10.0) 0 0 0 2 (0.8)
Serious adverse event 14 (12.1) 1 (5.0) 3 (7.5) 5 (5.1) 7 (8.9) 16 (6.7)
NOTE. Adverse events were classiﬁed according to the Medical Dictionary for Regulatory Activities System (Version 18.1) by
preferred terms.
Q4W, every 4 weeks.
aBenign, malignant, and unspeciﬁed (including cysts and polyps): acrochordon (n ¼ 1, placebo; n ¼ 1, 210 mg); adenoma
benign (n ¼ 1, 210 mg); angiolipoma (n ¼ 1, 7 mg Q4W); bladder cancer (n ¼ 1, placebo); bone giant cell tumor benign (n ¼ 1,
210 mg); colon adenoma (n ¼ 1, placebo; n ¼ 1, 7 mg Q4W); hemangioma (n ¼ 1, placebo); leiomyoma (n¼ 1, placebo); lipoma
(n ¼ 1, 210 mg); prostatic adenoma (n ¼ 1, 210 mg); skin cancer (n ¼ 1, placebo); skin papilloma (n ¼ 2, placebo; n ¼ 2, 70 mg
Q4W); thyroid neoplasm (n ¼ 1, 21 mg Q4W); and uterine leiomyoma (n ¼ 2, placebo).
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4 weeks compared with placebo, interpretation was limited
by the small number of patients who provided data at weeks
8 and 24 and could have been affected by inadequate
exposure of drug later in the study. In a phase 2 trial of
patients with moderate-to-severe UC, treatment with etro-
lizumab 100 mg led to achievement of clinical remission in
21% of patients vs none with placebo at week 10, which is
higher than that observed in our study at week 8.22 How-
ever, clinical remission with etrolizumab was mainly re-
ported in patients who were naïve to TNF antagonists, a less
treatment-refractory population.
Based on the exposure–response analysis of the per-
centage of patients in remission and serum abrilumab
trough concentrations, remission rates associated with
abrilumab trough concentrations of 10 mg/mL are signif-
icantly different than placebo, suggesting maximal observed
remission rates are achieved with abrilumab trough con-
centrations of 10 mg/mL. This abrilumab trough serum
concentration is higher than exposure levels associated with
90% occupancy of a4b7 (90% effective concentration 0.09
mg/mL) from the single ascending dose study of abrilumab
in healthy volunteers.15
We observed signiﬁcant associations between baseline
a4b7 levels and change in Mayo Score and mucosal healing,
irrespective of treatment received during the study. Our
results show that higher baseline concentrations of a4b7
levels were a favorable prognostic indicator in UC disease
activity and Mayo Score response, but not a predictive
biomarker of abrilumab response. The association between
baseline a4b7 and overall outcome changes the probability
of response (based on a threshold change in Mayo Score) by
approximately 10% (depending on the dose) for a
doubling in a4b7 levels. In contrast to the expectation that
baseline a4b7 levels would be higher in patients who had
used a TNF antagonist, we found baseline a4b7 levels were
signiﬁcantly lower in patients with prior TNF antagonist
failure. Prior exposure to TNF antagonist treatment was not
found to affect abrilumab mean trough concentrations. The
results of our exposure–response analyses suggest that
greater abrilumab exposure might result in higher remis-
sion and response rates; there did not appear to be a cor-
relation between remission and response rates and
peripheral receptor occupancy.
Treatment with abrilumab for 8 weeks was well toler-
ated, with 95% of abrilumab-treated patients completing
the week-8 assessment and only 1 patient discontinuing
from the induction period for an AE. The most common AEs
reported with abrilumab were anticipated: non-serious in-
fections, gastrointestinal AEs, headache, and arthralgia. No
PML cases were reported. Overall, the safety and tolerability
of abrilumab do not appear to differ from those of vedoli-
zumab and etrolizumab. Anti–abrilumab-binding antibodies
were identiﬁed in 2 patients during the study, 1 each in the
70-mg and 210-mg groups; no neutralizing antibodies were
detected.
This study has some limitations. A systematic misalign-
ment of treatments led some patients randomized to the
abrilumab 7-mg group to erroneously receive 70 mg and
some randomized to the abrilumab 21-mg group to
erroneously receive placebo. However, a protocol amend-
ment permitting data from these patients to be analyzed
based on actual treatment received, without breaking the
study blind, allowed maintenance of trial integrity with
minimal change in power to detect treatment differences
between the 2 high-dose abrilumab groups and placebo. In
addition, this short-term study did not fully evaluate
continued treatment with abrilumab after induction of
remission at 8 weeks. Although we observed a trend toward
treatment effect at week 24 for the abrilumab 70-mg mul-
tidose group, longer-term, phase 3 studies evaluating clin-
ical remission and response rates beyond 24 weeks are
required to draw conclusions on the durability of treatment
response. Conclusions regarding treatment responses based
on prior TNF antagonist treatment are limited, but initial
ﬁndings suggest potential beneﬁt in TNF antagonist-naïve
and -experienced patients.
Conclusion
The results from this phase 2 study provide preliminary
evidence that abrilumab administered as multiple doses of
70 mg or a single dose of 210 mg might induce remission,
clinical response, and mucosal healing in patients with
moderate-to-severe UC. Overall, abrilumab has an accept-
able safety and tolerability proﬁle at the SC dosages
administered in this patient population. Our data further
support the mechanism of targeting the a4b7 pathway as a
therapeutic option for the management of moderate-to-se-
vere UC and the use of a4b7 levels as a potential prognostic
indicator in UC.
Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at https://doi.org/10.1053/
j.gastro.2018.11.035.
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Methods
Study Design
Based on the healthy volunteer studies, dose levels of 7
mg, 21 mg, and 70 mg were selected because they were
expected to achieve a4b7 integrin occupancy in peripheral
blood at or above 90%, 99%, and 99.9%, respectively,
through 24 weeks of treatment. The 7-mg dose was selected
to be “minimally efﬁcacious” compared with the higher
doses. The assumptions were that pharmacokinetic (PK)
proﬁles observed in patients with inﬂammatory bowel dis-
ease would be similar to those of healthy volunteers, re-
ceptor occupancy measured in healthy volunteers generally
would be predictive of receptor occupancy measured in
patients with inﬂammatory bowel disease, and efﬁcacy
would be correlated with sustained receptor occupancy, as
observed in the vedolizumab trials.
Pharmacokinetic and Pharmacodynamic
Assessments
The PK bioanalytical assay to determine abrilumab
serum concentration has been described previously.15,16
Brieﬂy, serum abrilumab concentrations were determined
with a validated immunoassay using the Meso Scale Dis-
covery (Gaithersburg, MD) electro-chemiluminescence
platform with a lower limit of quantiﬁcation of 10 ng/mL.
Selectivity and extent of interference testing were used to
address any endogenous molecules that could have caused
matrix interference.
Noncompartmental analysis of abrilumab serum con-
centration data was performed using Phoenix WinNonlin
6.4 software on a Citrix (Pharsight Corp, St Louis, MO) as
part of the validated PKS system on individual serum abri-
lumab concentrations to estimate the following PK param-
eters: maximum observed concentration achieved in plasma
after dose administration, time to maximum observed con-
centration, and area under the concentration–time curve
estimated using the linear trapezoidal method. Actual doses
administered and actual sampling times were used in the
noncompartmental analysis. Concentrations below a lower
limit of quantiﬁcation—10.0 ng/mL—were set to 0 before
data analysis.
Flow Cytometry
Receptor occupancy was measured for whole-blood spec-
imens from a sub-study of 129 patients by the Immunophe-
notyping and Absolute Counting assay, a validated
semiquantitative ﬂow cytometric assay. This assay was a
simpliﬁed version of the abrilumab receptor occupancy assay
described previously.15 Brieﬂy, a ﬂuorochrome-labeled
competing anti-a4b7 antibody (anti-a4b7–ROA1) was used to
measure free a4b7 levels, and a second ﬂuorochrome-labeled
noncompeting anti-b7 antibody (anti-a4b7–ROA2) was used
to measure total a4b7 receptor levels on T cells in peripheral
blood. Although aE integrin is not frequently recorded in pe-
ripheral blood, an antibody recognizing the aE integrin was
included in the ﬂow cytometry panel to exclude aEb7þ T cells
from the receptor occupancy analysis by electronic gating.
Cells were gated on CD45þ lymphocytes, CD3þ T cells,
and CD8 (as a surrogate for the CD4þ T-cell population)
and CD103 (aE) populations. Naïve CD4þ T cells were
further deﬁned as CCR7þ CD45RAþ and assessed in this
assay because abrilumab and anti-a4b7–ROA1 bound the
active and inactive forms of a4b7 on naïve and memory
CD4þ T cells, with similar in vitro titration results. Naïve
CD4þ T cells expressed a single homogenous a4b7 peak that
allowed for continuous monitoring of the level of a4b7
without interference of an a4b7
 peak. Baseline levels also
were analyzed for their ability to predict clinical outcomes
at week 8.
Absolute lymphocyte counts were determined using a 6-
color TBNK reagent with Trucount tubes (Becton, Dickinson
and Company, Franklin Lakes, NJ) for enumeration of CD3þ
T cells, CD3þCD4þ T cells, CD3þCD8þ T cells, CD16þ56þ
natural killer cells, and CD19þ B cells. Absolute counts of
CD4þ T-cell subsets were calculated by multiplying the
percentage of the subset by the absolute count of the parent
to generate a “relative-absolute” count. CD4þ T cell subsets
included memory CD4þ T cells (identiﬁed as CD45þ CD3þ
CD8 CD103 CD45RA) and central memory CD4þ T cells
(identiﬁed as CD45þ CD3þ CD8 CD103 CD45RA CCR7þ).
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Appendix A. Neurology Case Referral Adjudication Process Flowchart
GCSM, Global Clinical Site Management; GDL, Global Development Leader; GSM, Global Study Management; GSO, Global
Safety Ofﬁcer; PML AC, Progressive Multifocal Leukoencephalopathy Adjudication Committee.
1Amgen GCSM includes a Country Operations Manager and a Clinical Research Associate.
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Appendix B. Case Adjudication
Methodology—Case Deﬁnition
This appendix outlines the case deﬁnition for PML,
adapted from joint European Medicines Agency and US Food
and Drug Administration workshop (Transatlantic Work-
shop: Drug-Related Progressive Multifocal Leukoencephal-
opathy; July 25–26, 2011) with input from the Progressive
Multifocal Leukoencephalopathy Adjudication Committee.
Characteristic brain biopsy (evidence of PML from brain
biopsy examination): brain biopsy result with the classic
histopathologic triad of PML (histopathologic demyelin-
ation, enlarged oligodendroglial cells, bizarre astrocytes) in
addition to immunohistochemistry (John Cunningham [JC]
virus T antigen and JC virus VP1 capsid protein) or in situ
polymerase chain reaction (JC virus DNA) or electron mi-
croscopy (JC virions)
Clinical description (signs and symptoms compatible
with PML): presence of focal neurologic deﬁcits, including
new deﬁcits, that can be subacute in onset, or worsening
deﬁcits; with symptoms that can include behavior or per-
sonality changes, cognitive dysfunction, hemiparesis, lan-
guage disturbance, retrochiasmal visual ﬁeld defects, or
new-onset seizures (a single symptom is sufﬁcient to raise
the question of PML)
Level 1: Characteristic brain biopsy result OR clinical
description AND characteristic brain magnetic reso-
nance imaging (MRI) AND positive cerebrospinal ﬂuid
(CSF) polymerase chain reaction (PCR) test result for
JC virus DNA
Level 2: Clinical description AND characteristic brain
MRI OR clinical description AND positive CSF PCR test
result for JC virus DNA OR clinical description unclear
or not reported but characteristic brain MRI AND
positive CSF PCR test result for JC virus DNA
Level 3: Clinical description unclear or not reported AND
brain MRI nonspeciﬁc or not reported but positive
CSF PCR test result for JC virus AND immune recon-
stitution inﬂammatory syndrome after stopping
immunosuppression
Level 4: Insufﬁcient information AND not meeting
exclusion criteria in Level 5
Level 5: Neurologic assessment leading to alternative
diagnosis AND brain MRI not characteristic of PML, or
negative CSF PCR test result for JC virus DNA, or brain
biopsy result not characteristic of PML
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Appendix C. PML Adjudication Worksheet Form
MRI, magnetic resonance imaging; PML AC, Progressive Multifocal Leukoencephalopathy Adjudication Committee.
A
AMG 181
Site No. Subject ID No.
ADJUDICATION WORKSHEET FORM
This form captures the questions used for adjudication of PML.  Please answer all questions. 
Date of Form Completion by PML AC 
Member
DD                                  MMM                               YYYY
Event ID (provided by Amgen)  
Based on the information received in the site 
packet, does this subject event meet the criteria to 
be a case of PML?
PML
Not consistent with PML
Indeterminate
If you selected this to be a case of PML please state why? 
_____________________________________________________________________________
_____________________________________________________________________________
If you did not select this to be a case of PML please state why? 
_____________________________________________________________________________
_____________________________________________________________________________
Were the imaging information (eg, MRI films) of 
adequate quality to review and reach a decision?
Yes No 
Note: Please provide the completed form to the PML Adjudication Chair for completion of the final adjudication form using 
information above
Name of PML AC Member: 
Signature: ____________________  Date: ____________
March 2019 Abrilumab ph2b UC 957.e4
Supplementary Figure 1. Study design. Patients with moderate-to-severe UC were randomized to receive SC placebo or
abrilumab at 7 mg, 21 mg, 70 mg (on day 1, week 2, week 4, and every 4 weeks thereafter until week 24) or 210 mg (a single
dose on day 1 followed by placebo weeks 2 and 4 and every 4 weeks thereafter until week 24). aA systematic misalignment in
IP resulted in a ﬁnal allocation at a ratio different from that stipulated in the protocol. bPatients who did not achieve a response
at week 8 and had an inadequate response at week 12 or after were eligible to enter the OL period early. cPatients who
achieved a response and/or remission at week 8 and subsequently experienced disease worsening were eligible to enter the
OL period early. D, day; OL, open-label; Q3M, every 3 months.
Supplementary Figure 2. Systematic misalignment of treatment allocation in study. Owing to a systematic misalignment, all
patients who were randomized to receive 7 mg actually received 70 mg and all patients who were randomized to receive 21 mg
actually received placebo before the study was paused.
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Supplementary Figure 3. Systematic misalignment by IPIM vs active vial positions before study pause. *Primary label does
contain the text “A,” “B,” and “C.” A systematic misalignment in IP dosing before study pause occurred because of a
misalignment in the IPIM compared with the active vial positions in the package. Although the IPIM protocol identiﬁed “Vial
Position A” as the active IP (ie, abrilumab), in the actual package, the IP was in “Vial Position C.” The placebo, 70-mg, and 210-
mg treatment arms did not require dilution; the 21- and 7-mg treatment arms did require dilution. Dosing required 3
injections—3 syringes with 1 mL each. When 0.5 mL of vial A was diluted into placebo 4.5 mL for the 7-mg arm (lower row of
bottom panel), placebo was diluted into placebo; this vial was used to ﬁll syringe 1 (placebo). Vials B and C were used to ﬁll the
2 additional syringes (syringes 2 and 3, placebo and abrilumab 70 mg/mL, respectively). Each patient received all 3 injections
and therefore patients planned to receive abrilumab 7 mg actually received 70 mg. For the 21-mg arm (upper row of bottom
panel), 3 syringes were ﬁlled from a master vial that was created by diluting 0.5 mL of vial A into placebo 4.5 mL, which was
placebo diluted into placebo. Each patient received all 3 injections and therefore patients planned to receive abrilumab 21 mg
actually received placebo. Together, these resulted in the mis-dosing of patients randomized to the 7-mg dose to receive 70
mg and the 21-mg dose to receive placebo. This misalignment in vial positions described was at the root of mis-dosing in the
7- and 21-mg treatment arms. The Interactive Voice Response System/Interactive Web Response System used for
randomization was not implicated.
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Supplementary Figure 4. Consolidated Standards of Reporting Trials (CONSORT) ﬂow diagram. Patients with moderate-to-
severe UC were randomized to receive SC placebo (n ¼ 117), abrilumab 7 mg (n ¼ 22), 21 mg (n ¼ 40), 70 mg (n ¼ 100), and
210 mg (n ¼ 80). Efﬁcacy and safety populations through week 24 consisted of 354 randomized patients who received 1
dose of IP.
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Supplementary Figure 5. Exposure–response analysis of
percentage of patients in remission compared with abrilumab
trough concentration. Fraction of patients in remission at
week 8 by trough serum abrilumab concentration (Cmin)
decile. A P value <.05 for a decile indicates that the remission
rate in that decile is signiﬁcantly different than placebo. Lo-
gistic regression showed that Cmin was the best exposure
metric to describe remission status at week 8. Error bars
represent 95% CI around the mean for that decile group.
Cmin, minimum blood plasma concentration; GeoMean,
geometric mean.
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Supplementary Figure 6. Pharmacodynamic effect of abrilumab on a4b7. Average (± 95% CI) baseline-normalized (A) free
a4b7 receptor proﬁles on CD4
þ-naïve T cells, (B) total a4b7 receptor proﬁles on CD4
þ-naïve T cells, and (C) a4b7
hi central
memory CD4þ T cells after abrilumab administration in patients with UC. A single measurement of immunophenotyping re-
ceptor occupancy with absolute counts was performed for patients entering the open-label trial at week 12, 16, or 24. Values
at week 16 were entirely missing for the 7-mg and 21-mg groups and were imputed from the adjacent visits to allow the model
to be ﬁt without meaningfully affecting the interpretation of the plot. The number of patients per treatment group by visit is
shown at the top of the plot, with the exception of imputed values.
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Supplementary Figure 6. (continued).
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Supplementary Figure 6. (continued).
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Supplementary Figure 7. Relation between baseline levels of
a4b7 and prior TNF antagonist use. Geometric mean baseline
a4b7 levels per cell in patients with and without prior TNF
antagonist use were calculated using a linear model of log-
transformed data. 95% CIs and contrasts between groups
were performed. Means and intervals were back-transformed
for display.
Supplementary Figure 8. Relation between baseline levels of a4b7 on CD4
þ-naïve T cells and change in total Mayo Score at
week 8. Baseline levels of a4b7 on CD4
þ-naïve T cells and change in Mayo Score at week 8 were analyzed to determine the
ability of a4b7 levels to predict clinical outcomes. Each panel shows an individual dose group and the best-ﬁt linear regression
line for the 2 variables. Q4W, every 4 weeks.
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Supplementary Table 1.Summary of Response at Week 8
Placebo
Abrilumab
7 mg Q4W 21 mg Q4W 70 mg Q4W 210 mg
All patients, N 116 21 40 98 79
Non-adjusted response rate using
NRI, n (%)
30 (25.9) 3 (14.3) 20 (50.0) 48 (49.0) 37 (46.8)
Adjusted response rate using NRI, % 26.0 12.3 47.2 49.4 47.4
Difference, % (90% CI) — 13.7 (24.4 to 2.7) 21.2 (4.9–34.1) 23.4 (11.8–33.2) 21.4 (9.0–31.8)
OR (90% CI) 0.40 (0.13–1.22) 2.54 (1.29–5.02) 2.78 (1.71–4.52) 2.57 (1.53–4.31)
P value .18 .024 <.001 .003
Patients with TNF antagonist failure, n 70 5 10 50 38
Non-adjusted response rate using
NRI, n (%)
20 (28.6) 1 (20.0) 3 (30.0) 22 (44.0) 20 (52.6)
Adjusted response rate using NRI, % 27.1 21.3 31.7 41.1 51.9
Difference, % (90% CI) — 5.8 (26.4 to 36.3) 4.6 (26.8 to 24.7) 14.0 (2.1 to 26.7) 24.8 (6.9–38.7)
OR (90% CI) 0.73 (0.10–5.32) 1.25 (0.32–4.93) 1.88 (0.98–3.59) 2.91 (1.45–5.84)
P value .79 .79 .11 .012
Patients naïve to TNF antagonist 44 16 30 43 41
Non-adjusted response rate using
NRI, n (%)
10 (22.7) 2 (12.5) 17 (56.7) 23 (53.5) 17 (41.5)
Adjusted response rate using NRI, % 17.7 6.9 42.9 49.8 34.7
Difference, % (90% CI) — 10.8 (20.6 to 7.5) 25.2 (4.8–40.1) 32.1 (14.1–45.5) 17.0 (0.8 to 30.1)
OR (90% CI) 0.34 (0.09–1.40) 3.50 (1.46–8.38) 4.61 (2.03–10.50) 2.47 (1.10–5.59)
P value .21 .018 .002 .067
NOTE. Response at week 8 was deﬁned as a decrease from baseline in total Mayo Score of 3 points and 30% decrease
from baseline, with an accompanying decrease in the sub-score for rectal bleeding of 1 point or the absolute sub-score for
rectal bleeding of 0 or 1.
N, number of patients in full analysis set; n, number of patients who reached response status at week 8; Q4W, every 4 weeks.
Supplementary Table 2.Summary of Mucosal Healing at Week 8
Placebo
Abrilumab
7 mg Q4W 21 mg Q4W 70 mg Q4W 210 mg
All patients, N 116 21 40 98 79
Non-adjusted mucosal healing rate using
NRI, n (%)
25 (21.6) 3 (14.3) 6 (15.0) 32 (32.7) 23 (29.1)
Adjusted mucosal healing rate using NRI, % 16.8 12.2 13.9 32.2 29.8
Difference, % (90% CI) — 4.6 (14.9 to 11.3) 3.0 (11.9 to 9.4) 15.3 (4.8–24.0) 13.0 (1.7–22.1)
OR (90% CI) 0.69 (0.21–2.22) 0.80 (0.32–1.97) 2.34 (1.35–4.07) 2.10 (1.15–3.82)
P value .60 .68 .011 .041
Patients with TNF antagonist failure, n 70 5 10 50 38
Non-adjusted mucosal healing rate using
NRI, n (%)
16 (22.9) 0 1 (10) 13 (26.0) 15 (39.5)
Adjusted mucosal healing rate using NRI, % 16.0 10.6 13.2 18.8 40.6
Difference, % (90% CI) — 5.4 (18.4 to 29.1) 2.8 (16.1 to 22.0) 2.8 (10.5 to 12.7) 24.6 (7.6–37.6)
OR (90% CI) 0.62 (0.03–12.34) 0.80 (0.13–5.10) 1.22 (0.57–2.58) 3.59 (1.60–8.08)
P value .79 .84 .67 .009
Patients naïve to TNF antagonist, n 44 16 30 43 41
Non-adjusted mucosal healing rate using
NRI, n (%)
9 (20.5) 3 (18.8) 5 (16.7) 17 (39.5) 8 (19.5)
Adjusted mucosal healing rate using NRI, % 11.7 9.9 10.8 43.3 13.8
Difference, % (90% CI) — 1.8 (12.1 to 17.1) 0.9 (10.3 to 14.2) 31.7 (14.6–44.2) 2.1 (12.1 to 11.7)
OR (90% CI) 0.83 (0.22–3.08) 0.91 (0.30–2.77) 5.80 (2.23–15.12) 1.21 (0.46–3.18)
P value .82 .89 .003 .74
NOTE. Mucosal healing was deﬁned as the absolute sub-score for recto-sigmoidoscopy of 0 or 1.
N, number of patients in full analysis set; n, number of patients who reached mucosal healing status at week 8; Q4W, every 4
weeks.
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Supplementary Table 3.Summary of Remission at Week 24
All patients
Placebo
(n ¼ 116)
Abrilumab
7 mg Q4W
(n ¼ 21)
21 mg Q4W
(n ¼ 40)
70 mg Q4W
(n ¼ 98)
210 mg
(n ¼ 79)
Non-adjusted remission rate
using NRI, n (%)
14 (12.1) 2 (9.5) 7 (17.5) 22 (22.4) 10 (12.7)
Adjusted remission rate using NRI, (%) 12.5 7.0 13.8 22.9 12.4
Difference, % (90% CI) — 5.5 (13.1 to 7.8) 1.3 (10.7 to 9.9) 10.4 (0.9–18.1) 0.1 (7.0 to 8.9)
ORa vs placebo (90% CI) — 0.53 (0.14–2.04) 1.12 (0.46–2.72) 2.08 (1.12–3.88) 0.99 (0.47–2.07)
P valueb — .44 .83 .052 .98
N, number of patients in full analysis set; n, number of patients who reached remission status at week 24; Q4W, every 4 weeks.
aThe OR and P value were obtained from a logistic regression model including the factors of treatment group, stratiﬁcation
factors (prior vs no prior TNF antagonist use and pre- vs post-protocol amendment 3) and baseline total Mayo Score, using
NRI. An OR >1.0 indicates a higher remission rate for the abrilumab treatment group vs placebo.
bAll P values are nominal.
Supplementary Table 4.Summary of Response at Week 24
All patients
Placebo
(N ¼ 116)
Abrilumab
7 mg Q4W
(N ¼ 21)
21 mg Q4W
(N ¼ 40)
70 mg Q4W
(N ¼ 98)
210 mg
(N ¼ 79)
Non-adjusted response rate
using NRI, n (%)
29 (25.0) 4 (19.0) 16 (40.0) 35 (35.7) 24 (30.4)
Adjusted response rate using NRI, (%) 25.8 16.4 36.4 36.3 30.3
Difference, % (90% CI) — 9.4 (21.5, 8.2) 10.6 (5.3 to 23.1) 10.5 (0.8–20.0) 4.5 (7.4 to 14.2)
ORa vs placebo (90% CI) — 0.56 (0.20–1.56) 1.64 (0.82–3.28) 1.64 (1.00–2.70) 1.25 (0.72–2.15)
P valueb — 0.35 0.24 0.10 0.50
N, number of patients in full analysis set; n, number of patients who reached response status at week 24; Q4W, every 4 weeks.
aThe OR and P value were obtained from a logistic regression model including the factors of treatment group, stratiﬁcation
factors (prior vs no prior TNF antagonist use and pre- vs post-protocol amendment 3), and baseline total Mayo Score using
NRI. An OR >1.0 indicates a higher remission rate for the abrilumab treatment group vs placebo.
bAll P values are nominal.
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Supplementary Table 5.Summary of Mucosal Healing at Week 24
All patients
Placebo
(n ¼ 116)
Abrilumab
7 mg Q4W
(n ¼ 21)
21 mg Q4W
(n ¼ 40)
70 mg Q4W
(n ¼ 98)
210 mg
(n ¼ 79)
Non-adjusted healing rate using
NRI, n (%)
22 (19.0) 4 (19.0) 15 (37.5) 33 (33.7) 19 (24.1)
Adjusted healing rate using NRI, (%) 18.2 14.9 32.5 34.7 24.1
Difference, % (90% CI) — 3.3 (14.5 to 13.6) 14.3 (0.9 to 26.1) 16.5 (5.7–25.4) 5.9 (5.0 to 14.7)
ORa vs placebo (90% CI) — 0.79 (0.28–2.23) 2.16 (1.04–4.48) 2.39 (1.39–4.10) 1.43 (0.78–2.61)
P valueb — .71 .082 .008 .33
N, number of patients in full analysis set; n, number of patients who reached mucosal healing status at week 24; Q4W, every 4
weeks.
aThe OR and P value were obtained from a logistic regression model including the factors of treatment group, stratiﬁcation
factors (prior vs no prior TNF antagonist use and pre- vs post-protocol amendment 3), and baseline recto-sigmoidoscopy
score using NRI. An OR >1.0 indicates a higher remission rate for the abrilumab treatment group vs placebo.
bAll P values are nominal.
Supplementary Table 6.Summary of Sustained Remission at Weeks 8 and 24
All patients
Placebo
(n ¼ 116)
Abrilumab
7 mg Q4W
(n ¼ 21)
21 mg Q4W
(n ¼ 40)
70 mg Q4W
(n ¼ 98)
210 mg
(n ¼ 79)
Observed remission rate, n/N1 (%) 3/32 (9.4) 0/8 (0.0) 1/22 (4.5) 8/46 (17.4) 3/32 (9.4)
Non-adjusted remission rate
using NRI, n/N (%)
3/116 (2.6) 0/21 (0.0) 1/40 (2.5) 8/98 (8.2) 3/79 (3.8)
Difference, % (90% CI) 2.6 (5.0 to 0.2) 0.1 (4.8 to 4.6) 5.6 (0.4–10.7) 1.2 (3.1 to 5.5)
N, number of patients in analysis set; n, number of patients who reached remission status at weeks 8 and 24 (ie, sustained
remission); N1, number of patients with total Mayo Score at weeks 8 and 24; Q4W, every 4 weeks.
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Supplementary Table 7.Summary of Corticosteroid-Free Remission at Week 24
All patients
Placebo
(n ¼ 116)
Abrilumab
7 mg Q4W
(n ¼ 21)
21 mg Q4W
(n ¼ 40)
70 mg Q4W
(n ¼ 98)
210 mg
(n ¼ 79)
Observed remission rate, n/N1 (%) 5/32 (15.6) 0/8 (0.0) 3/22 (13.6) 7/46 (15.2) 4/32 (12.5)
Non-adjusted healing rate using NRI, n/N (%) 5/116 (4.3) 0/21 (0.0) 3/40 (7.5) 7/98 (7.1) 4/79 (5.1)
Difference, % (90% CI) 4.3 (7.4 to 1.2) 3.2 (4.3 to 10.7) 2.8 (2.5 to 8.1) 0.8 (4.4 to 5.9)
N, number of patients in analysis set; n, number of patients who reached corticosteroid-free remission at week 24; N1, number
of subjects with total Mayo Score at week 24; Q4W, every 4 weeks.
Supplementary Table 8.Mean (SD) PK Parameter Estimates After SC Administration of Abrilumab
Treatment group tmax (d), median (IQR) Cmax (mg/mL) AUCtau (d ∙ mg/mL) AUCinf (d ∙ mg/mL)
7 mg (n ¼ 3) 8.0 (6.7–13.9) 2.48 (3.06) 51.2 (65.7) NR
21 mg (n ¼ 5–6a) 6.5 (0.0–14.8) 6.43 (2.80) 125 (54.6) NR
70 mg (n ¼ 5) 7.0 (6.7–13.9) 18.3 (9.08) 363 (197) NR
210 mg (n ¼ 4–9b) 7.9 (6.8–14.0) 27.5 (10.4) NR 610 (317)
NOTE. Data are mean (SD) unless otherwise noted.
AUCinf, area under concentration–time curve from time 0 to inﬁnity; AUCtau, area under concentration–time curve during dosing
interval tau (28 days); Cmax, maximum observed concentration; tmax, time to maximum observed concentration; IQR, inter-
quartile range; NR, not reported.
aN ¼ 6 for Cmax and tmax; n ¼ 5 for AUCtau.
bN ¼ 9 for Cmax and tmax; n ¼ 4 for AUCinf.
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Supplementary Table 10.Change From Baseline CRP Concentration at Weeks 8 and 24
All patients Placebo (n ¼ 116)
Abrilumab
7 mg Q4W (n ¼ 21) 21 mg Q4W (n ¼ 40) 70 mg Q4W (n ¼ 98) 210 mg (n ¼ 79)
Week 8
Mean change (SE) 2.90 (1.75) 4.10 (1.95) 0.54 (1.37) 1.19 (1.13) 1.11 (1.52)
LS mean change (90% CI) 1.72 (3.6 to 0.2) 1.34 (3.7 to 1.0) 0.29 (2.0 to 2.5) 2.51 (4.1 to 1.0) 0.78 (2.8 to 1.2)
LS mean treatment difference (90% CI) — 0.38 (2.6 to 3.3) 2.01 (0.8 to 4.8) 0.79 (3.3 to 1.7) 0.94 (1.8 to 3.7)
P value — .83 .24 .60 .58
Week 24
Mean change (SE) 4.20 (2.18) 2.36 (3.74) 3.18 (1.30) 0.18 (2.28) 2.95 (3.02)
LS mean change (90% CI) 4.72 (6.6 to 2.8) 2.17 (7.2 to 2.9) 2.54 (2.1 to 7.2) 0.14 (4.0 to 3.7) 2.72 (5.9 to 0.4)
LS mean treatment difference (90% CI) — 2.55 (2.8 to 7.9) 7.26 (2.2–12.3) 4.58 (0.1–9.0) 2.00 (1.8 to 5.8)
P value — .44 .019 .091 .38
LS, least squares; Q4W, every 4 weeks; SE, standard error.
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Supplementary Table 11.Change From Baseline FCP Concentration at Weeks 8 and 24
All patients Placebo (n ¼ 116)
Abrilumab
7 mg Q4W (n ¼ 21) 21 mg Q4W (n ¼ 40) 70 mg Q4W (n ¼ 98) 210 mg (n ¼ 79)
Week 8
Mean change (SE) 115.79 (283.67) 30.15 (339.27) 440.98 (225.14) 319.34 (338.08) 354.52 (182.29)
LS mean change (90% CI) 65.63 (318.7 to 450.0) 198.29 (1048.1 to 651.6) 648.24 (876.2 to 420.3) 325.41 (800.8 to 150) 531.32 (739.3 to 323.3)
LS mean treatment difference
(90% CI)
— 263.92 (1224.8 to 697.0) 713.88 (1233.7 to 194.1) 391.04 (996.2 to 214.1) 596.95 (1032.8 to 161.1)
P value — .65 .024 .29 .024
Adjusted >50% decrease rate,
using NRI
28.5 30.5 30.2 45.4 28.6
Treatment difference % (90% CI) 2.0 (22.8 to 19.1) 1.7 (15.9 to 15.1) 17.0 (3.6 to 27.9) 0.1 (13.1 to 10.8)
ORa vs placebo (90% CI) 1.10 (0.39–3.12) 1.09 (0.48–2.44) 2.09 (1.19–3.66) 1.01 (0.55–1.85)
P value .88 .87 .030 .98
Week 24
Mean change (SE) 1122.20 (442.48) 104.64 (612.83) 663.62 (470.36) 506.22 (295.00) 326.50 (262.78)
LS mean change (90% CI) 826.53 (967.6 to 685.4) 162.88 (990.5 to 1316.3) 734.52 (1114.6 to 354.5) 612.60 (790.4 to 434.8) 515.08 (766.8 to 263.3)
LS mean treatment difference
(90% CI)
— 989.41 (186.7 to 2165.5) 92.01 (317.2 to 501.2) 213.93 (9.8 to 437.6) 311.45 (23.5 to 599.4)
P value — .17 .71 .12 .075
LS, least squares; Q4W, every 4 weeks; SE, standard error.
aThe OR and P value were obtained from a logistic regression model including the factors of treatment group, stratiﬁcation factor (prior vs no prior TNF antagonist use and
pre- vs post-protocol amendment 3), and baseline FCP value using NRI. An OR >1.0 indicates a higher >50% FCP decrease rate for the abrilumab treatment group vs
placebo.
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